

Vessels per 0.5mm²
40
30
20
10
0
Vehicle
Cmpd. 1 (3mg/kg)
Cmpd. 1 (10mg/kg)
Cmpd. 1 (30mg/kg)
Mean values for n=3 tumors per condition

Fig. 1A



CD31
100µm
Vehicle
Average vessel # per 0.5mm² = 26.9
CD31
100µm
3mg/kg Cmpd. 1
Average vessel # per 0.5mm² = 33.4
CD31
100µm
30mg/kg Cmpd. 1
Average vessel # per 0.5mm² = 17.6

Fig. 1B



CD8 positive cells
(per 500mm² area)
250
200
150
100
50
0
Treatment
Vehicle
PD-1 5mg/kg
Cmpd 1 10mg/kg
Cmpd 1 10mg/kg +
PD-1 5mg/kg

Fig. 2A



CD8
100µm
Vehicle
Average CD8+ T-cell #
per 0.5mm² = 34.8
CD8
100µm
Anti-PD-1 (5mg/kg)
Average CD8+ T-cell #
per 0.5mm² = 49.8
CD8
100µm
10mg/kg Cmpd.
1 + anti-PD-1
Average CD8+ T-cell #
per 0.5mm² = 96.1

Fig. 2B




Fig. 3A




Fig. 3B




Fig. 3C

Growth curve stops once a single tumor reach the defined endpoint size (2000 mm^3)



Tumor Volume (mm3)
2500
2000
1500
1000
500
0
0
10
20
30
Days Post Initial Dosing
Vehicle
PD-1 5mg/kg
Cmpd 1 1mg/kg + PD-1 5mg/kg
Cmpd 1 3mg/kg + PD-1 5mg/kg
Cmpd 1 10mg/kg + PD-1 5mg/kg
Cmpd 1 30mg/kg + PD-1 5mg/kg

Fig. 4



Percent survival
100
75
50
25
0
0
10
20
30
40
Days Post Initial Dosing
Vehicle
PD-1 5mg/kg
Cmpd 1 30mg/kg
Cmpd 1 30mg/kg + PD-1 5mg/kg
Cmpd 1 single agent vs combo
P value = 0.0219
Cmpd 1 combo vs PD-1
P value <0.0001

Fig. 5



A
Tumor Volume (mm³)
2500
2000
1500
1000
500
0
0
10
20
30
40
Days (From Treatment Start)
Vehicle
Cmpd. 1 (30mg/kg)
anti-PD-1 (10mg/kg)
Cmpd. 1 (30mg/kg) + anti-PD-1

Fig. 6A



B
Conditional Survival (%)
100
80
60
40
20
0
0
10
20
30
40
Days (From Treatment Start)
Vehicle
Cmpd. 1 (30mg/kg)
anti-PD-1 (10mg/kg)
Cmpd. 1 (30mg/kg) + anti-PD-1

Fig. 6B



25k apoptotic Jurkats
Total Red Object Area (µm²/Image)
Time (Hours)
n=3

Fig. 7A




50k apoptotic Jurkats
Total Red Object Area (µm²/Image)
Time (Hours)
n=3

Fig. 7B



LLOQ, lower limit of quantitation; PIB, powder in a bottle; tab, tablet. Note: Data below LLOQ (0.5 ng/mL) are shown as ½ LLOQ for illustration purposes only.

Fig. 8